...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Egyptian Journal of Hospital Medicine >Comparative Study between Fibro-Test and Egy-Score as Non-Invasive Markers for Assessment of Hepatic Fibrosis in Chronic Hepatitis C
【24h】

Comparative Study between Fibro-Test and Egy-Score as Non-Invasive Markers for Assessment of Hepatic Fibrosis in Chronic Hepatitis C

机译：Fibro-Test和Egy-Score作为非侵入性标记物评估慢性丙型肝炎肝纤维化的比较研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Backgound: Liver fibrosis (LF) occurs in response to almost all causes of chronic liver injury. Assessing LF is important for both predicting disease progression and monitoring efficacy of therapeutic measures. Most noninvasive tests of liver fibrosis were developed with the aim of discriminating between "insignificant", (F0-F1) by METAVIR and clinically "significant" fibrosis ( F2) by METAVIR or for identifying or excluding established cirrhosis in patients with well compensated chronic liver disease. Both these aims are clinically the most relevant. Aim: We aimed to compare the diagnostic accuracy of FibroTest and Egy-Score as predictors of stage of hepatic fibrosis in a prospectively enrolled cohort of Egyptian patients with chronic hepatitis C. Patients and Methodlogy: Twenty patients, treatment na?ve chronic hepatitis C patients were enrolled. They were 16 males (80%) and 4 females (20%) mean age of these patients was 53.55 +14.3 (rang 18_73 years). The study was carried out in the Department of Gastroenterology and Hepatology, Elhussin hospital, Al-Azhar University during the period between March 2016 and March 2018. Results: Our results showed a highly significant positive correlation between stage of hepatic fibrosis by METAVIR and fibrotest. Our results showed a highly significant positive correlation between stage of hepatic fibrosis by METAVIR and EGY-SCOR. Our scores depend mainly on simple routinely used laboratory parameters (total bilirubin, albumin, platelet count) in addition to age and 2 non routine tests (CA 19-9 and Alpha-2- Macroglobulin). Although this panel needs to be done in validated laboratories, the cost of our score is much cheaper than other well-known and patented tests such as FibroTest and the net results of both methods nearly the same. Conclusion: Egy-Score can be applied easily in clinical practice to exclude severe hepatic fibrosis/cirrhosis in patients with contraindication for liver biopsy or those who are reluctant to do it. Egy-score would need further valida?tion to be regarded as an alternative to liver biopsy. Recommendations: Physician should be careful when interpreting elevated levels of tu?mor markers CA 19-9 and CA 125 in patients with chronic liver disease as this could be a benign elevation related to hepatic fibrosis and not necessarily due to underlying malignancies. Elevation of the tumor markers such as CA19.9 have been associated with cholestasis in liver disease patients and this may give false positive results for our scores which give Limitations to our study.
机译：背景：肝纤维化（LF）发生于几乎所有引起慢性肝损伤的原因。评估LF对于预测疾病进展和监测治疗措施的有效性都很重要。大多数肝纤维化的非侵入性检查都是为了区分METAVIR的“不明显”（F0-F1）和METAVIR的临床上的“重大”纤维化（F2）或鉴定或排除慢性肝病患者的肝硬化疾病。这两个目标在临床上都是最相关的。目的：我们的目的是比较预期纳入的埃及慢性丙型肝炎患者队列中FibroTest和Egy-Score作为肝纤维化分期预测指标的诊断准确性。患者和方法：二十名患者，未接受过治疗的慢性丙型肝炎患者被录取了。他们是男性的16位男性（80％）和4位女性（20％）的平均年龄为53.55 +14.3（范围18_73岁）。该研究于2016年3月至2018年3月期间在Al-Azhar大学Elhussin医院消化内科和肝病科进行。结果：我们的结果显示，METAVIR肝纤维化的阶段与纤维化试验之间存在高度显着的正相关。我们的结果显示，METAVIR和EGY-SCOR在肝纤维化阶段之间存在高度显着的正相关。除了年龄和2个非常规测试（CA 19-9和Alpha-2-Macroglobulin）外，我们的得分主要取决于简单的常规实验室参数（总胆红素，白蛋白，血小板计数）。尽管该小组的工作需要在经过验证的实验室中进行，但我们的评分成本比其他知名且获得专利的测试（例如FibroTest）便宜得多，而且两种方法的最终结果几乎相同。结论：Egy-Score可在临床实践中轻松应用，以排除肝活检禁忌症患者或不愿意做的严重肝纤维化/肝硬化患者。 Egy评分将需要进一步验证才能被视为肝活检的替代方法。建议：在解释慢性肝病患者中肿瘤标志物CA 19-9和CA 125的水平升高时，医师应小心，因为这可能是与肝纤维化有关的良性升高，而不一定是潜在的恶性肿瘤。肝病患者的胆汁淤积与肿瘤标志物（例如CA19.9）的升高有关，这可能会给我们的评分带来假阳性结果，从而限制了我们的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号